跳到正文
原文
Endpoints News 生物医药· Kyle LaHucik·· 16 天前AI 评分41

明慧生物将甲状腺眼病药物在日本的权利出售给百年药企

China biotech Minghui does thyroid eye disease deal for $110M upfront

AI 导读

明慧生物将其处于III期临床试验的甲状腺眼病药物在日本的权利以1.1亿美元的价格出售给了一家百年专业药企。

正文

A Chi­nese biotech is sell­ing the Japan­ese rights for its Phase 3 thy­roid eye dis­ease drug to a 106-year-old spe­cial­ty phar­ma long known for its …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

来源:Endpoints News 生物医药 · endpoints.news